Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RY 103

Next Previous
X
Search
Drug Profile

RY 103

Alternative Names: NS 101; RY-103

Latest Information Update: 12 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Reyon Pharmaceutical
  • Developer Neuracle Science; Reyon Pharmaceutical
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Sensorineural hearing loss
  • Phase I Neurodegenerative disorders

Most Recent Events

  • 19 Jan 2024 Phase-I/II clinical trials in Sensorineural hearing loss (Treatment-experienced) in South Korea (IV) (NCT06249919)
  • 22 Dec 2022 Neuracle Science completes a phase I trial in Neurodegenerative disorders (In volunteers) in Canada (IV) (NCT05143463)
  • 03 Dec 2021 Pharmacodynamics data from a preclinical study in Neurodegenerative disorders released by Neuracle Science (Neuracle Science website, December 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top